Digestive System Diseases

Symptoms and General Pathology

All Conditions

Neoplasms

Infections

Rare Diseases

Liver Cirrhosis

Carcinoma

Carcinoma, Hepatocellular

Liver Diseases

Fatty Liver

Hepatitis A

Hepatitis C

Hepatitis

Hepatitis B

Hepatitis B, Chronic

Liver Neoplasms

Non-alcoholic Fatty Liver Disease

Hepatitis C, Chronic

Gastrointestinal Diseases

Hepatitis, Viral, Human

Virus Diseases

Communicable Diseases

Enterovirus Infections

Picornaviridae Infections

RNA Virus Infections

Blood-Borne Infections

Flaviviridae Infections

Hepadnaviridae Infections

DNA Virus Infections

Fibrosis

Gastrointestinal Neoplasms

Digestive System Neoplasms

Hepatitis, Chronic

Chronic Disease

Disease Attributes

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Chronic Graft Versus Host Disease

Visceral Steatosis

Hematinics

All Drugs and Chemicals

Liver Extracts

Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Liver cancer surveillance every 3 months

Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Liver cancer surveillance every 6 months

Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Liver cancer surveillance annually

Qing Xie, MD

Honglian Gui, MD,PhD

Qing Xie, MD, PhD.

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Exploration of A Holistic Management Procedure for Liver Cancer Surveillance in Improving Liver Cancer's Early Diagnosis Efficacy in Chinese Population: Single-Center, Prospective, Observational Real-world Study in EASTERN China

The disease types include but are not limited to hepatitis B, hepatitis C, cirrhosis, MAFLD

The disease types include but are not limited to hepatitis B, hepatitis C, cirrhosis, MAFLD; early diagnosis of HCC is defined as the patient with stage CNLC Ia, Ib and IIa

The compliance rates for subjects with very high-risk, high-risk, medium-risk, and low-risk; the compliance rate is defined the same as above

The proportion of patients who are first diagnosed with HCC at early stage to all the patients diagnosed as liver cancer in the study, from the start of the study to the completion of follow-up. Early diagnosis is defined as the patient with stage CNLC Ia, Ib and IIa.

Regular follow-up is defined as the average difference between the actual treatment time and the theoretical treatment time equal or less than 1/3

* Actual visit interval: actual visit date - previous visit date ② Theoretical visit interval: theoretical visit date (the date that physician advise to return to hospital for visit) - previous visit date ③ Follow-up compliance = (②-①)/② ④ Patient with regular follow-up is defined as the patient whose mean follow-up compliance is equal to, or less than 1/3

  * The compliance of the study is defined as the proportion of subjects with regular follow-up to all subjects in the study.

The proportion of very high-risk, high-risk, medium-risk, and low-risk subjects to the whole subject population

The proportion of very high-risk, high-risk, medium-risk and low-risk subjects to the whole subject population

The early diagnosis rate of liver cancer of subjects with very high-risk, high-risk, medium-risk, and low-risk at initial screening, respectively

The 3-year cumulative incidence of liver cancer for subjects with very high-risk, high-risk, medium-risk, and low-risk, respectively

Ruijin Hospital

Director of Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Spots Global Cancer Trial Database for liver cancer surveillance annually